Aurinia Pharmaceuticals Inc
Closed
SectorHealthcare
16.41 4.72
Overview
Share price change
24h
Min
15.57
Max
16.64
Income | -176M 34M |
|---|---|
Sales | 591K 78M |
P/E Sector Avg | 7.088 49.888 |
EPS | 0.25 |
Profit margin | 44.212 |
Employees | 128 |
EBITDA | 2.7M 50M |
Next Earnings | 30 Jul 2026 |
|---|
Market Cap | -80M 2B |
|---|---|
Previous open | 11.69 |
Previous close | 16.41 |
News Sentiment
By Acuity
50%
50%
155 / 344 Healthcare
Aurinia Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Aurinia Pharmaceuticals Inc Forecast
Sentiment
By Acuity
155 / 344 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
